Skip to main content

Advertisement

Table 1 Reported global annual product sales by calendar year for selected medicines according to company annual reports (2004–2017) (in million USD)a

From: Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib

YearSovaldi® (sofosbuvir) Gilead [47]Herceptin® (trastuzumab) Roche & Genentech [48]Gleevec/Glivec® (imatinib) Novartis [49]
2004N/A11621634
2005N/A17172170
2006N/A31422554
2007N/A40273050
2008N/A47363944
2009N/A48453944
2010N/A52124265
2011N/A59364659
2012N/A63014675
201313965654693
201410,28368401237
2015527668001219
2016400169183323
201796471541943
Total20,66334,27743,310
  1. aAmounts rounded to millions. Trastuzumab sales have been converted from CHF to USD using historical exchange rates